Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6600002.pdf
Reference26 articles.
1. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH (1998) Advanced epithelial ovarian cancer: 1998 consensus statement. Ann Oncol 10: S87–S92
2. Bolis G, Scarfone G, Luchini L, Ferraris C, Zanaboni F, Presti M, Giardina G, Villa A, Parazzini F (1994) Response to second-line weekly cisplatin chemotherapy in ovarian cancer previously treated and with a cisplatin or carboplatin-based regimen. Eur J Cancer 30A: 1764–1768
3. Chambers SK, Chambers JT, Kohorn EI, Schwartz PE (1987) Etoposide plus cis-diamminedichloroplatinum as salvage therapy in advanced epithelial ovarian cancer. Gynecol Oncol 27: 233–240
4. de Wit R, van der Burg MEL, van der Gaast A, Logmans A, Stoter G, Verweij J (1994) Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum containing chemotherapy. Ann Oncol 5: 656–657
5. Eisenhauer EA, ten Bokkel Huinink W, Swenerton KD, Gianni L, Myles J, van der Burg ME, Kerr I, Vermorken JB, Buser K, Colombo N (1994) European-Canadian randomised trial of Taxol in relapsed ovarian cancer: High vs low and long vs short infusion. J Clin Oncol 12: 2654–2666
Cited by 66 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions;Current Issues in Molecular Biology;2023-09-28
2. A random forest-based metabolic risk model to assess the prognosis and metabolism-related drug targets in ovarian cancer;Computers in Biology and Medicine;2023-02
3. Chemotherapy in Gynaecological Cancers and Newer Developments;Gynecological Oncology;2022
4. The systemic treatment of recurrent ovarian cancer revisited;Annals of Oncology;2021-06
5. Involvement of selective GABA-A receptor subtypes in amelioration of cisplatin-induced neuropathic pain by 2’-chloro-6-methyl flavone (2’-Cl-6MF);Naunyn-Schmiedeberg's Archives of Pharmacology;2020-11-22
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3